Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Euroscreen S.A. - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 30 | Code: MRS - 7045

 

Global Markets Direct’s, ‘Euroscreen S.A. Product Pipeline Review 2015’, provides an overview of the Euroscreen S.A.’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of Euroscreen S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of Euroscreen S.A. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Euroscreen S.A.’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Euroscreen S.A.’s pipeline products

 

Reasons to buy

 

Evaluate Euroscreen S.A.’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Euroscreen S.A. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Euroscreen S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Euroscreen S.A. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Euroscreen S.A.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Euroscreen S.A. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents
 

Table of Contents 2
List of Tables 4
List of Figures 4
Euroscreen S.A. Snapshot 5
Euroscreen S.A. Overview 5
Key Information 5
Key Facts 5
Euroscreen S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Euroscreen S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Euroscreen S.A. - Pipeline Products Glance 14
Euroscreen S.A. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Euroscreen S.A. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Euroscreen S.A. - Drug Profiles 17
ESN-364 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ESN-282 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ESN-314 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ESN-502 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules to Target GPCR for Metabolic Diseases 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Euroscreen S.A. - Pipeline Analysis 22
Euroscreen S.A. - Pipeline Products by Target 22
Euroscreen S.A. - Pipeline Products by Route of Administration 23
Euroscreen S.A. - Pipeline Products by Molecule Type 24
Euroscreen S.A. - Pipeline Products by Mechanism of Action 25
Euroscreen S.A. - Recent Pipeline Updates 26
Euroscreen S.A. - Dormant Projects 27
Euroscreen S.A. - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28

 

Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30

 

List of Tables
 

Euroscreen S.A., Key Information 5
Euroscreen S.A., Key Facts 5
Euroscreen S.A. - Pipeline by Indication, 2015 7
Euroscreen S.A. - Pipeline by Stage of Development, 2015 8
Euroscreen S.A. - Monotherapy Products in Pipeline, 2015 9
Euroscreen S.A. - Partnered Products in Pipeline, 2015 10
Euroscreen S.A. - Partnered Products/ Combination Treatment Modalities, 2015 11
Euroscreen S.A. - Out-Licensed Products in Pipeline, 2015 12
Euroscreen S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Euroscreen S.A. - Phase I, 2015 14
Euroscreen S.A. - Preclinical, 2015 15
Euroscreen S.A. - Discovery, 2015 16
Euroscreen S.A. - Pipeline by Target, 2015 22
Euroscreen S.A. - Pipeline by Route of Administration, 2015 23
Euroscreen S.A. - Pipeline by Molecule Type, 2015 24
Euroscreen S.A. - Pipeline Products by Mechanism of Action, 2015 25
Euroscreen S.A. - Recent Pipeline Updates, 2015 26
Euroscreen S.A. - Dormant Developmental Projects,2015 27
Euroscreen S.A., Other Locations 28"


 

List of Figures
 

Euroscreen S.A. - Pipeline by Top 10 Indication, 2015 7
Euroscreen S.A. - Pipeline by Stage of Development, 2015 8
Euroscreen S.A. - Monotherapy Products in Pipeline, 2015 9
Euroscreen S.A. - Pipeline by Top 10 Target, 2015 22
Euroscreen S.A. - Pipeline by Top 10 Route of Administration, 2015 23
Euroscreen S.A. - Pipeline by Top 10 Molecule Type, 2015 24
Euroscreen S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing